The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: A nine-month follow-up;Eficacia y tolerancia del piribedil como terapia adjunta a la levodopa en pacientes con enfermedad de Parkinson: Seguimiento de nueve meses

Revista de Neurologia

Volumn 38, Issue 8, 2004, Pages 715-719

  Salazar Tortolero, Gabriel ^a,c   Wix Ramos, R ^b   Salazar Aladren P ^b   Jimenez Leon J C ^b  

^a Grup Barcelona Parkinson   (Spain)

^b Hospital Policlínico Valencia   (Venezuela)

^c Grupo Barcelona Parkinson   (Spain)

Author keywords

Dopamine agonist; Parkinsonism; Piribedil

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PIRIBEDIL; PLACEBO; TRIVASTIL RETARD;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FINGER; HUMAN; HYPOTHERMIA; LEG AGILITY; LEG MOVEMENT; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PHYSICAL CAPACITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RIGIDITY; SOMNOLENCE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING;

EID: 2942715292     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3808.2003461     Document Type: Article

References (24)

1. Tolosa E. Advances in the pharmacological management of Parkinson disease. J Neural Transm Suppl 2003; 64: 65-78.
2. Murata M, Kanazawa I. Repeated levodopa administration reduces the ability of dopamine storage and abolishes the super sensitivity of dopamine receptor in the striatum of intact rats. Neurosci Res 1993; 16: 15-23.
3. Stocci F, Berardelli A, Vacca L, Thomas A, De Pandia MF, Modugn-Valente M, et al. Combination of two different agonists in the management of Parkinson's disease. Neurol Sci 2002; 23 (Suppl 2): S115-6.
4. Rascol O, Befrel-Courbon C, Payaux P, Ferreira J. The management of patients with early Parkinson's disease. Adv Neurol 2003; 91: 203-11.
5. Inzemberg R, Schechtman E, Nisipeanu P. Cabergolide, pramipexole and ropirinole used as monotherapy in early Parkinson's disease. An evidence-based comparison. Drugs Aging 2003; 20: 847-55.
6. Navan P, Findly LJ, Jeffs JA, Pearce RK, Bain PG. Double-blind, single dose, cross over study of the effects of pramipexole, pergolide and placebo on rest tremor and UPDRS part III in Parkinson's disease. Mov Disord 2003; 18: 176-80.
7. Im JH, Ha JH, Cho IS, Lee MC. Ropirinole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003; 250: 97.
8. Sharma J, Macmahon D, Steward D. Dopamine agonists for Parkinson's disease. Lancet 2002; 360: 1138.
9. Sage JL, Parkes D. Pergolide therapy in Parkinson's disease. A double-blind, placebo-controlled study. Clin Neuropharmacol 1985; 8: 2602-65.
10. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50 (Suppl 3): S1-57.
11. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93.
12. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. J Neurol 1992; 239 (Suppl 1): S28-34.
13. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with Parkinson's disease: a 6-months, randomized, placebo-controlled study. Mov Disord 2003; 18: 418-25.
14. Ziegler M, Rondot P. Action of piribedil in Parkinson's disease multicenter study. Press Med 1999; 28: 1414-8.
15. Sweet RD, Wasterlain CG, McDowel FH. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther 1974; 16: 1077-82.
16. Callaghan N, Fitzpatrick E, O'Mahony JB. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. Acta Neurol Scand 1975; 52: 179-86.
17. Ziegler M, Rascol O, Del Signore S, Castro-Caldas A. Efficacy of piribedil in adjuntion to levodopa in a 6-month randomized placebo-controlled study in early Parkinson's disease. Neurology 2000; 54 (Suppl 3): 280.
18. Evrard Y. Piribedil, a dopamine-agonist. Acta Ther 1991; 1: 16-20.
19. Chanelet J, Phelate M. Action of piribedil on the membrane of a cholinergic neuron of the cockroach (Periplaneta americana). Adv Neurol 1975; 9: 337-45.
20. Brefel-Courbon C, Peyro-Sant Paul H, Senard JM, Monstastruc JL, Rascol O. Alpha-2-adrenoceptor antagonists: a new approach for Parkinson's disease? CNS Drugs 1998; 10: 189-207.
21. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-88.
22. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Sleep attacks in Parkinson's disease patients taking ropirinole or pramipexole. Neurology 1999; 52: 1908-10.
23. Jiménez-Jiménez FJ, Velazco I, De Toledo M, Sabed Y, Zurdo J, Ortiz-Pareja M, et al. Prueba de múltiple latencia en un paciente con episodios de sueño inducidos por pergolide. Rev Neurol 2002; 34: 1140-1.
24. García-Ruiz PJ, Hernández J, Cantarero S, Fanjul S. Ataques de sueño y mesilato de pergolide. Neurologia 2001; 16: 92.